References
References


14. *Biomedical Business International*, VII(120/121); 191, Nov. s, 1984 (a newsletter based in Tustin, CA).


41. duBuy, Y., Financial Management Section, National institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, personal communications, Nov. 6, 1984; Dec. 28, 1984.


44. Fanton, R., Norden Laboratories, Lincoln, NE, personal communication, Nov. 21, 1984.


56. Gallo, R. C., National Cancer Institute, National Institutes of Health, Bethesda, MD, personal communication, Sept. 6, 1984.
74. Hunsmann, G., remarks made during a discussion of vaccines for HTLV viruses at the HTLV Symposium, sponsored by the National Cancer Institute.
Institute, National Institutes of Health, Bethesda, MD, Dec. 6 and 7, 1984.
99a. McKusick, L., Project Director, AIDS Behavioral Research Project, University of California,


121. Pitlick, F., Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, comments made at the NHLBI AIDS Working Group meeting, Bethesda, MD, Sept. 10, 1984.


128. Safer Sex Committee of New York, “Healthy Sex Is Great Sex” (brochure), New York, NY, no date.


142. Talbot, B., National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, personal communication, Nov. 5, 1984.


143. U.S. Congress, House Committee on Appropriations, Subcommittee on Labor, Health, and Human Services, Hearings on Departments of Labor, HHS, Education Appropriations for 1984, parts 3 and 4a (Washington, DC, 1983).


163. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Division


176. Wells, S. A., Jr., Chairman, Board of Scientific Counselors, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD, letter to J.B. Wyngaarden, Director, National Institutes of Health, Nov. 7, 1984.


